TABLE 2.
Last chemotherapy prior to transplant
| Patients in CR, number (%) |
Patients in CRp, number (%) |
Patients in MLFS (%) |
P value | |
|---|---|---|---|---|
| MEC1 | 27 (13%) | 5 (11%) | 2 (11%) | <0.001 |
| HiDAC2 | 92 (45%) | 16 (36%) | 1 (5%) | |
| CLAG or CLAG-M3 | 4 (2%) | 4 (9%) | 1 (5%) | |
| FLAG, FLAG-I, FLAG-IM4 |
11 (5%) | 7 (16%) | 3 (16%) | |
| Decitabine | 11 (5%) | 2 (4%) | 2 (11%) | |
| Other5 | 61 (30%) | 11 (24%) | 10 (52%) |
1
MEC = Mitoxantrone, etoposide, cytarabine
2
HiDAC = High-dose cytarabine
3
CLAG = Cladribine, cytarabine, filgrastim; CLAG-M = CLAG plus mitoxantrone
4
FLAG = Fludarabine, cytarabine, filgrastim; FLAG-I = FLAG plus idarubicin; FLAG-IM = FLAG-I plus gemtuzumab ozogamicin
5
Includes clofarabine, all-trans retinoic acid, sorafenib, plerixafor, 5+2, 7+3, gemtuzumab ozogamicin alone, mitomycin, imatinib, and azacitidine.